U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H38O5S
Molecular Weight 462.642
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIXOCORTOL PIVALATE

SMILES

[H][C@@]12CC[C@](O)(C(=O)CSC(=O)C(C)(C)C)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)CC[C@]34C

InChI

InChIKey=BISFDZNIUZIKJD-XDANTLIUSA-N
InChI=1S/C26H38O5S/c1-23(2,3)22(30)32-14-20(29)26(31)11-9-18-17-7-6-15-12-16(27)8-10-24(15,4)21(17)19(28)13-25(18,26)5/h12,17-19,21,28,31H,6-11,13-14H2,1-5H3/t17-,18-,19-,21+,24-,25-,26-/m0/s1

HIDE SMILES / InChI

Description

Tixocortol is a synthetic steroid with topical anti-inflammatory properties. In form of Tixocortol pivalate, also known as Pivalone, it is used to treat the inflammatory and allergic manifestations of the rhino-pharynx: allergic rhinitis, acute and chronic congestive rhinitis, vasomotor rhinitis. In addition, it has been shown to be a useful agent for assessing corticosteroid contact dermatitis, particularly for hydrocortisone-type derivatives. Labeled adverse effects are: itchy nose, dryness of the nasal mucosa, edema of the face mucosa, cataract, glaucoma, Cushing syndrome, skin thinning.

Approval Year

1994
149
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
PubMed

PubMed

TitleDatePubMed
[Epidemiologic surveillance of contact allergens. The "monitoring series" of IVDK (Information Network ofDermatologic Clinics for Detection and Scientific Evaluation of Contact Allergy].
2003 Aug
[The value of allergy survey in a retrospective series of 40 patients with burning-mouth syndrome (stomatodynia)].
2008 Feb
Concordance of patch test results with four new TRUE test allergens compared with the same allergens from Chemotechnique.
2009 Jan
Positive patch-test reactions to propylene glycol: a retrospective cross-sectional analysis from the North American Contact Dermatitis Group, 1996 to 2006.
2009 Jan-Feb
[Allergic contact dermatitis due to corticosteroids: a 3-year retrospective study in a hospital skin allergy unit].
2009 May
Pattern of corticosteroid allergy in Thailand.
2010 Jul-Aug
Patents

Patents

JP2011518796A
15

Sample Use Guides

In Vivo Use Guide
1 to 2 sprays of 1 % Suspension in each nostril 2 to 4 times daily.
Route of Administration: Nasal
Name Type Language
TIXOCORTOL PIVALATE
MART.   USAN   VANDF   WHO-DD  
USAN  
Official Name English
TIXOCORTOL 21-PIVALATE
MI  
Common Name English
TIXOCORTOL 21-PIVALATE [MI]
Common Name English
TIXOCORTOL PIVALATE [VANDF]
Common Name English
11β,17-Dihydroxy-21-mercaptopregn-4-ene-3,20-dione 21-pivalate
Common Name English
JO-1016
Code English
TIXOCORTOL PIVALATE [USAN]
Common Name English
PREGN-4-ENE-3,20-DIONE, 21-((2,2-DIMETHYL-1-OXOPROPYL)THIO)-11,17-DIHYDROXY-, (11.BETA.)-
Systematic Name English
TIXOCORTOL PIVALATE [MART.]
Common Name English
TIXOCORTOL-21-PIVALATE
Common Name English
Tixocortol pivalate [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000185508
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
NCI_THESAURUS C211
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
Code System Code Type Description
WIKIPEDIA
TIXOCORTOL PIVALATE
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107112
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
NCI_THESAURUS
C152668
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
CHEBI
63564
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
EVMPD
SUB04894MIG
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
CAS
55560-96-8
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID30970904
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
PUBCHEM
15052414
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
DAILYMED
6K28E35M3B
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
FDA UNII
6K28E35M3B
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
DRUG BANK
DBSALT001131
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
NDF-RT
N0000184306
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY Cell-mediated Immunity [PE]
USAN
Y-58
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
RXCUI
38336
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY RxNorm
SMS_ID
100000091288
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
NDF-RT
N0000171131
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY Allergens [Chemical/Ingredient]
ECHA (EC/EINECS)
259-706-4
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
MESH
C019112
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY
NDF-RT
N0000175629
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY Increased Histamine Release [PE]
MERCK INDEX
m10911
Created by admin on Fri Dec 15 15:01:32 GMT 2023 , Edited by admin on Fri Dec 15 15:01:32 GMT 2023
PRIMARY Merck Index
ACTIVE MOIETY
Structure of TIXOCORTOL
SUBSTANCE RECORD
Structure of TIXOCORTOL PIVALATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966